Akouos — Investor Presentation (December 2020)
26 slides from Akouos's investor presentation, Dec 1, 2020
Slide 1: December 2020
December 2020
Slide 2: Forward-looking statements
This presentation includes “forward-looking statements” within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995, including, but not limited to: our expectation about timing and execution of anticipated milestones, including our
Slide 3: Genetic Medicine Platform Focused on Inner Ear Disorders
2 Genetic Medicine Platform Focused on Inner Ear Disorders Attractive Market with High Unmet Need ~466mm people worldwide with disabling hearing loss, including ~34mm children Multimodal Precision Genetic Medicine Platform Building a platform that enables development of multiple vector-mediated gene
Slide 4: Experienced Management Team with Otology, Genetic Medicine, and Rare Disease Expertise
3 Experienced Management Team with Otology, Genetic Medicine, and Rare Disease Drug Development Expertise Emmanuel Simons, Ph.D., M.B.A. Founder, Chief Executive Officer Michael McKenna, M.D. Founder, Chief Medical Officer Morgan Molloy Chief Corporate Development Officer Rabia Gurses Ozden, M.D. Ch
Slide 5: How We Hear
4 How We Hear Ear Drum Round Window Membrane (“RWM”) Spiral Ganglion Cells Auditory Nerve Oval Window Hensen’s Cells Spiral Ganglion Cells Claudius Cells Inner Hair Cells Outer Hair Cells Pillar Cells Inner Border Cells • Sound enters the ear through the external auditory canal of the outer ear, whe
Slide 6: Overview of Genetically-Driven Hearing Loss
5 Overview of Genetically-Driven Hearing Loss Autosomal Recessive Autosomal Dominant Nonsyndromic Syndromic > 75 genes > 30 genes > 48 > 10 1 of 500 newborns has disabling hearing loss Genetic Causes (80%) Syndromic (15-20%) Nonsyndromic (75-80%) Recessive (80%) Dominant (19%) Mitochondrial & X-Link
Slide 7: Anatomy and Biology of the Inner Ear Are Ideal for One-Time Genetic Medicines
6 The Anatomy and Biology of the Inner Ear Are Ideal for One-Time Genetic Medicines While the unique anatomical challenges of delivering to the inner ear have hindered genetic medicine development for hearing disorders, we believe Akouos is uniquely positioned to overcome these delivery challenges O
Slide 8: The Akouos Precision Genetic Medicine Platform
7 The Akouos Precision Genetic Medicine Platform Novel Delivery Approach Proprietary AAV Vector Library Multimodal Capabilities Gene transfer targeting loss-of- function mutations Gene knockdown or editing targeting toxic gain-of-function or dominant negative mutations Therapeutic protein expression
Slide 9: Novel, Minimally Invasive Delivery Approach
• Designed to allow for the safe and effective delivery of product candidates through the round window membrane • Minimally invasive device delivers product candidates in a fixed volume and at a controlled flow rate • Design allows for distribution of product candidates across the full length of the
Slide 10: AAVAnc80 Exhibits High Transduction Efficiency Compared to Other AAV Capsids
9 AAVAnc80 Exhibits High Transduction Efficiency Compared to Other AAV Capsids Capsid AAV1 AAV2 AAV8 AAVAnc80 Dose 21x 3.5x 7x 1x Multiple independent investigations have shown increased hair cell transduction efficiency of AAVAnc80 relative to other AAV capsids in mouse and non-human primate models
Slide 11: Multi-Dose Tropism Study in Cynomolgus Macaque
10 Multi-Dose Tropism Study in Cynomolgus Macaque Showed Efficient Inner Hair Cell Transduction at Three Weeks 75 to 100% of inner hair cells (IHCs) express transgene at 6E10 vg / cochlea in the cynomolgus macaque I n n e r H a i r C e l l T r a n s d u c t i o n ( % ) 100 80 60 40 20 0 0.06 0.5 4 3
Slide 12: Dual Vector Approach for Larger Transgenes
11 The High Transduction Efficiency of AAVAnc80 Coupled with Local Delivery to the Inner Ear Compartment Allows for a Dual Vector Approach for Larger Transgenes Ability to deliver transgenes that are larger than 5 kilobases in size creates the potential for broader treatment of genetically-driven he
Slide 13: AAVAnc80 Efficiently Transduces Multiple Cell Types in the Inner Ear
12 AAVAnc80 Efficiently Transduces Multiple Cell Types in the Inner Ear • Conducted nonclinical studies across three different non-human primate models using GFP as a reporter gene delivered by AAVAnc80 • AAVAnc80 can efficiently transduce multiple target cell populations throughout the cochlea in t
Slide 14: Multimodal Capabilities Address Broad Range of Inner Ear Disorders
13 Multimodal Capabilities Create Potential to Address a Broad Range of Monogenic and Non-Monogenic Inner Ear Disorders Gene Transfer Single Vector Dual Vector Gene Knockdown RNA-interference Therapeutic Protein Expression Gene Editing Nuclease- based Non- nuclease- based CLRN1 OTOF Undisclosed auto
Slide 15: Deep Pipeline Highlights Breadth of Platform
Deep Pipeline Highlights Breadth of Platform Product Candidate or Development Program (Indication) Estimated Prevalence (US and EU) Stage of Development Next Planned Milestone Discovery Preclinical Phase 1/2 Pivotal Hair Cells AK-OTOF (OTOF-mediated Hearing Loss) 20,000 ▪ IND Submission AK-CLRN1 (Us
Slide 16: AK-OTOF Overview
AK-OTOF Overview • AK-OTOF encodes otoferlin, a protein that enables the sensory cells of the ear to release neurotransmitter vesicles, activating auditory neurons • AK-OTOF • Use AAVAnc80 as a delivery vehicle for the OTOF gene • Administer product candidate directly into the inner ear • Delivery M
Slide 17: Dual Vector Delivery of AK-OTOF Restored ABR Thresholds in Mice
Dual Vector Delivery of AK-OTOF Led to Restoration of ABR Thresholds and Long-Term Hearing Recovery in Mice AK-OTOF utilizes a dual vector approach to restore long-term hearing in knock-out mouse models – one AAVAnc80 vector carries the 5’ fragment of OTOF gene and the other AAVAnc80 vector carries
Slide 18: Single Dose of AK-OTOF Restored Cochlear Function in Mature Mice
17 A Single Dose of AK-OTOF Restored Cochlear Function in Mature Mice Lacking Otoferlin Time re Click Onset (msec) Time re Click Onset (msec) Time re Click Onset (msec) Wild-Type Vehicle Control Otoferlin KO + Vehicle Control Otoferlin KO + AAVAnc80-hOTOF In a nonclinical study, a single dose of AK-
Slide 19: Planned AK-OTOF Phase 1/2 Clinical Trial
Planned AK-OTOF Phase 1/2 Clinical Trial Part A Dose Escalation Assess: Safety, tolerability, and bioactivity Part B Cohort Expansion Assess: Safety and effectiveness Up to 5-year clinical follow-up (1) Based on pre-IND meeting with FDA in September 2019. Key Eligibility • Individuals with OTOF-medi
Slide 20: AK-antiVEGF Overview
AK-antiVEGF Overview • AK-antiVEGF encodes a secreted inhibitor of vascular endothelial growth factor (VEGF) to treat vestibular schwannoma • AK-antiVEGF • Progress and Status • Nonclinical data in mice confirm anti-VEGF protein expression • Initial NHP study supports preliminary tolerability of chr
Slide 21: AK-antiVEGF for the Treatment of Vestibular Schwannoma
20 AK-antiVEGF for the Treatment of Vestibular Schwannoma Human Data Demonstrate Ability of Systemic VEGF Inhibitor to Improve Hearing and Reduce Tumor Volume in Some Patients with Vestibular Schwannoma Nonclinical Data in NHPs Demonstrate Delivery of AK-antiVEGF is Well- Tolerated and Results in Po
Slide 22: AK-CLRN1 Overview
21 AK-CLRN1 Overview • AK-CLRN1 encodes clarin-1, a protein believed to modulate cochlear hair cell mechanotransduction and synaptic function, for patients with Usher syndrome type 3A • AK-CLRN1 • Progress and Status • Published data demonstrate ability of AAV-mediated delivery of mouse CLRN1 to res
Slide 23: Proof of Concept Data: AAV-mediated Delivery of CLRN1
22 Proof of Concept Data: AAV-mediated Delivery of CLRN1 Recovered Hearing in a Knock-Out Mouse Model •Nonclinical data demonstrated hearing preservation in the KO-TgAC1 mouse model, which recapitulates the auditory phenotype observed in human USH3A patients •AAV delivery of mouse Clrn1 with its end
Slide 24: Key Advantages to Our Manufacturing Process
23 Key Advantages to Our Manufacturing Process Low dose requirements given small size and compartmentalized nature of the inner ear Targeted delivery and high transduction efficiency alleviate the need for large scale production Exclusive access to AAVAnc Vectors for inner ear provides opportunity t
Slide 25: Internal Manufacturing Capabilities May Provide Competitive Advantage
Internal Manufacturing Capabilities May Provide Competitive Advantage Expertise in Gene Therapy and Gene Editing • Expertise covers development from vector design through drug product manufacture • Developing scalable manufacturing capabilities, which may allow for significant control over process d
Slide 26: Recent Accomplishments and Upcoming Milestones
25 Recent Accomplishments and Upcoming Milestones Recent Highlights Upcoming Milestones • Upsized IPO: ~$224mm in net proceeds • Expanded leadership team and board of directors • General alignment with FDA on path to IND submission for AK-antiVEGF; target timing for IND submission is 2022 • Product